Global Oncology Investment Expertise

We are a global investment advisor with a focus on oncology. Nextech is run by an experienced team of experts and supported by key opinion leaders in oncology.

We deploy our expertise to invest equity in cancer companies with game changing discoveries.

Alfred Scheidegger

PhD, Founding Partner & CEO

Thilo Schroeder

PhD, Partner

Kristina Kakalacheva

PhD, Associate

Marco Weibel

CFO

Rocco Sgobbo

Head of Business Development

David M. Livingston

Chairman, Deputy Director, DFCI/Harvard Cancer Center

Karl-Heinz Altmann

Professor, Swiss Federal Institute of Technology in Zurich

Philip D. Greenberg

Head, Program in Immunology, Fred Hutchinson CRC

William G. Kaelin

Professor, Harvard Medical School

Sir Bruce A.J. Ponder

Head, Department of Oncology, University of Cambridge

Charles L. Sawyers

Chair, Human Oncology Program, MSKCC

Paul Workman

Chief Executive and President, The Institute of Cancer Research, London

Kai Wucherpfennig

Chair, Department of Cancer Immunology and Virology, DFCI

Alfred Scheidegger

PhD, Founding Partner & CEO

Thilo Schroeder

PhD, Partner

Kristina Kakalacheva

PhD, Associate

Marco Weibel

CFO

Rocco Sgobbo

Head of Business Development

David M. Livingston

Chairman, Deputy Director, DFCI/Harvard Cancer Center

Karl-Heinz Altmann

Professor, Swiss Federal Institute of Technology in Zurich

Philip D. Greenberg

Head, Program in Immunology, Fred Hutchinson CRC

William G. Kaelin

Professor, Harvard Medical School

Sir Bruce A.J. Ponder

Head, Department of Oncology, University of Cambridge

Charles L. Sawyers

Chair, Human Oncology Program, MSKCC

Paul Workman

Chief Executive and President, The Institute of Cancer Research, London

Kai Wucherpfennig

Chair, Department of Cancer Immunology and Virology, DFCI

Agensys

Acquired

Fully human antibody drug conjugates for pancreatic cancer.
Blueprint

IPO

Highly selective kinase inhibitors for genomically defined cancer subsets

Cleave Biosciences

Clinical Phase I

Small molecule inhibitors targeting protein homeostasis.
Ganymed

Acquired

Ideal monoclonal antibodies for cancer treatment.

ImaginAB

Clinical Phase II

Antibody fragments for imaging of cancer.
Jounce Therapeutics

Clinical Phase I

Immunotherapeutics to create highly durable cancer treatments

Kura Oncology

IPO

Small molecules that target cancer signaling pathways
MacroGenics

Full Exit

Antibodies for cancer immunotherapy

Molecular MD

Market

Cancer genotyping for targeted cancer therapies.
Palyon

Liquidated

Implantable drug pumps for palliative care and diabetes.

Peloton

Clinical Phase I

Small-molecule programs with a distinct target and mechanism of action.
Sunesis

Partial Exit

Small molecules for acute myeloid leukemia.

Telormedix

Sale of shares

Targeted immunity in cancer and other diseases.
TetraLogic

Full Exit

Small molecule Smac mimetics for treatment of cancers.

TRACON

IPO

Antibodies targeting endoglin in cancer angiogenesis.

Corporate Presentation

Get it now.

28.09.2016

Tracon Pharmaceuticals announces a strategic...
26.09.2016

Jounce Therapeutics appoints Stephen Farrand,PhD,...

Corporate Presentation

Get it now.

Agensys

Acquired

Fully human antibody drug conjugates for pancreatic cancer.
Blueprint

IPO

Highly selective kinase inhibitors for genomically defined cancer subsets
Cleave Biosciences

Clinical Phase I

Small molecule inhibitors targeting protein homeostasis.
Ganymed

Acquired

Ideal monoclonal antibodies for cancer treatment.

ImaginAB

Clinical Phase II

Antibody fragments for imaging of cancer.
Jounce Therapeutics

Clinical Phase I

Immunotherapeutics to create highly durable cancer treatments
Kura Oncology

IPO

Small molecules that target cancer signaling pathways
MacroGenics

Full Exit

Antibodies for cancer immunotherapy

Molecular MD

Market

Cancer genotyping for targeted cancer therapies.
Palyon

Liquidated

Implantable drug pumps for palliative care and diabetes.
Peloton

Clinical Phase I

Small-molecule programs with a distinct target and mechanism of action.
Sunesis

Partial Exit

Small molecules for acute myeloid leukemia.

Telormedix

Sale of shares

Targeted immunity in cancer and other diseases.
TetraLogic

Full Exit

Small molecule Smac mimetics for treatment of cancers.
TRACON

IPO

Antibodies targeting endoglin in cancer angiogenesis.

Agensys

Acquired

Fully human antibody drug conjugates for pancreatic cancer.
Blueprint

IPO

Highly selective kinase inhibitors for genomically defined cancer subsets

Cleave Biosciences

Clinical Phase I

Small molecule inhibitors targeting protein homeostasis.
Ganymed

Acquired

Ideal monoclonal antibodies for cancer treatment.

ImaginAB

Clinical Phase II

Antibody fragments for imaging of cancer.
Jounce Therapeutics

Clinical Phase I

Immunotherapeutics to create highly durable cancer treatments

Kura Oncology

IPO

Small molecules that target cancer signaling pathways
MacroGenics

Full Exit

Antibodies for cancer immunotherapy

Molecular MD

Market

Cancer genotyping for targeted cancer therapies.
Palyon

Liquidated

Implantable drug pumps for palliative care and diabetes.

Peloton

Clinical Phase I

Small-molecule programs with a distinct target and mechanism of action.
Sunesis

Partial Exit

Small molecules for acute myeloid leukemia.

Telormedix

Sale of shares

Targeted immunity in cancer and other diseases.
TetraLogic

Full Exit

Small molecule Smac mimetics for treatment of cancers.

TRACON

IPO

Antibodies targeting endoglin in cancer angiogenesis.

Global Oncology Investment Expertise

Alfred Scheidegger

PhD, Founding Partner & CEO

Thilo Schroeder

PhD, Partner

Kristina Kakalacheva

PhD, Associate

Marco Weibel

CFO

Rocco Sgobbo

Head of Business Development

David M. Livingston

Chairman, Deputy Director, DFCI/Harvard Cancer Center

Karl-Heinz Altmann

Professor, Swiss Federal Institute of Technology in Zurich

Philip D. Greenberg

Head, Program in Immunology, Fred Hutchinson CRC

William G. Kaelin

Professor, Harvard Medical School

Sir Bruce A.J. Ponder

Head, Department of Oncology, University of Cambridge

Charles L. Sawyers

Chair, Human Oncology Program, MSKCC

Paul Workman

Chief Executive and President, The Institute of Cancer Research, London

Kai Wucherpfennig

Chair, Department of Cancer Immunology and Virology, DFCI

Alfred Scheidegger

PhD, Founding Partner & CEO

Thilo Schroeder

PhD, Partner

Kristina Kakalacheva

PhD, Associate

Marco Weibel

CFO

Rocco Sgobbo

Head of Business Development

David M. Livingston

Chairman, Deputy Director, DFCI/Harvard Cancer Center

Karl-Heinz Altmann

Professor, Swiss Federal Institute of Technology in Zurich

Philip D. Greenberg

Head, Program in Immunology, Fred Hutchinson CRC

William G. Kaelin

Professor, Harvard Medical School

Sir Bruce A.J. Ponder

Head, Department of Oncology, University of Cambridge

Charles L. Sawyers

Chair, Human Oncology Program, MSKCC

Paul Workman

Chief Executive and President, The Institute of Cancer Research, London

Kai Wucherpfennig

Chair, Department of Cancer Immunology and Virology, DFCI

Portfolio Companies

Game Changing Cancer Companies

Agensys

Acquired

Blueprint

IPO

Cleave Biosciences

Clinical Phase I

Ganymed

Acquired

ImaginAB

Clinical Phase II

Jounce Therapeutics

Clinical Phase I

Kura Oncology

IPO

MacroGenics

Full Exit

Molecular MD

Market

Palyon

Liquidated

Peloton

Clinical Phase I

Sunesis

Partial Exit

Telormedix